Broadly, my research focuses on understanding the mechanisms driving symptoms of gastrointestinal dysfunction caused by cancer therapy, including diarrhoea, constipations, gastroparesis. To-date, my work has been focussed on toxicities caused by the anti-myeloma agent, bortezomib, including gastrointestinal symptoms, but also peripheral neuropathy, with a particular focus on understanding the role of the gut microbiota in driving these side effects. By improving our understanding of how the gut microbiota may contribute to these bortezomib-related toxicities, I hope to develop microbial-based strategies to mitigate these toxicities and ultimately improve the quality of life and survival outcomes of people with myeloma.

In addition to this line of research, I am also interested in understanding gastrointestinal toxicities caused by other anti-myeloma agents, including lenalidomide, and also more targeted anti-cancer agents, e.g. TKIs.